Tempest Therapeutics receives Nasdaq notice over minimum bid price deficiency
TPST•Tempest Therapeutics received a Nasdaq notice after its common stock closed below $1 for 30 consecutive business days. It has until May 3, 2027, to meet the minimum bid requirement, with a possible additional 180-day compliance period.
1. Nasdaq compliance deadline
Tempest Therapeutics received a Nasdaq noncompliance notice on November 4, 2026, after its common stock remained below $1 for 30 consecutive business days. The notice does not immediately affect its listing or business operations. To regain compliance, the stock must close at or above $1 for at least 10 consecutive business days before May 3, 2027.
2. Possible extension
The company may be eligible for an additional 180-day compliance period, subject to listing requirements and a written commitment to conduct a reverse stock split if necessary. Failure to qualify for an extension or regain compliance could lead to delisting, subject to appeal.
